Peptide Cycling Strategies for Optimal Fat Loss

Introduction

Cycling fat loss peptides means alternating weeks of use with weeks off. Community guides say growth hormone (GH) releasing peptides lose effect with steady use. The human evidence is thin, and off weeks may give back lost fat. As of October 2026, no trial has tested a cycling schedule for any fat-loss peptide.

Fat Loss Peptide Categories

GH Secretagogues (Fat Mobilization)

Peptide	Primary Action	Fat Loss Evidence
Ipamorelin	GH pulse	No human fat-loss trial
CJC-1295	Sustained GH elevation	Fat not measured in trials
GHRP-2/6	Strong GH pulse	No fat-loss trials
Tesamorelin	Targeted visceral fat	Prescription medicine (HIV lipodystrophy)

Fragment Peptides and Melanotan II

Peptide	Mechanism	Evidence
Fragment 176-191	HGH fragment	Human data come from AOD-9604
AOD-9604	Modified Fragment	Failed oral weight-loss trials
Melanotan II	Melanocortin agonist	Not a fat-loss drug; melanoma case reports

In AOD-9604's largest trial (OPTIONS, 536 adults with obesity), oral doses of 0.25-1 mg daily didn't beat placebo at 12 weeks, and development stopped in 2007, per FDA's 2024 briefing. FDA found no human data on injected use. Our Fragment 176-191 page has more.

Cycling Protocols for Fat Loss

In a 16-week hexarelin study in 12 older adults, the GH response fell about 45% and recovered four weeks after stopping. GH and IGF-1 stayed raised over two years of daily MK-677, but fat mass didn't change. Nobody has measured tolerance for ipamorelin or CJC-1295 (see ipamorelin for fat loss and CJC-1295 for fat loss).

Stopping has a cost on tesamorelin's label. In HIV lipodystrophy trials, visceral fat fell 14-18% over 26 weeks; people switched to placebo regained most of it over the next 26 weeks, while those who stayed on held steady.

Standard Fat Loss Cycle

Community and vendor guides repeat this template; we found no primary source or trial behind it.

Phase	Duration	Peptides	Focus
Loading	2-4 weeks	Full dose daily	Establish effects
Maintenance	8-12 weeks	Standard dosing	Sustained use
Taper	1-2 weeks	Reduce 25% weekly	Gradual discontinuation
Off	4-6 weeks	None	Meant to restore response

Aggressive Cut Protocol

Guides also describe a 12-week version for GHRPs: build up to full dose over weeks 1-2, then full dose 3x daily through week 8, reduce to 2x daily for weeks 9-10, and stay off for weeks 11-12. Forum users more often report 5 days on and 2 off, for Mod GRF 1-29 with ipamorelin or for tesamorelin at 1-2 mg nightly. AOD-9604 users commonly describe 300 mcg daily for 12 weeks.

Stacking for Fat Loss

The GH stack (ipamorelin + CJC-1295) is near-universal among users, but no controlled trial has tested the pair. We found no human fat-loss trials of Fragment 176-191 used alone or with ipamorelin.

Timing Considerations

Common community rules, none tested:

Fasted dosing
Avoiding insulin spikes around injections
Dosing before cardio
An evening dose to match the overnight GH pulse

Optimizing Fat Loss Results

A caloric deficit does most of the work; guides often cite 20-25% below maintenance with protein at 2-2.5 g/kg. Prescription GLP-1 medicines have Phase 3 weight-loss data no peptide here has (see how fat-loss methods compare).

Monitoring Progress

Adjusting Protocol

Situation	Common User Response
Plateau after 4+ weeks	Adding a compound or taking a break
Excessive fatigue	Lowering the dose or eating more
Rising fasting glucose	Stopping (MK-677 and tesamorelin raised glucose in trials)
Side effects	Lowering dose or frequency

What We Still Don't Know

Whether off weeks restore the response to ipamorelin or CJC-1295.
How much fat returns during breaks outside tesamorelin's trials.